MX9805255A - Antagonistas de receptor de vitronectina. - Google Patents
Antagonistas de receptor de vitronectina.Info
- Publication number
- MX9805255A MX9805255A MX9805255A MX9805255A MX9805255A MX 9805255 A MX9805255 A MX 9805255A MX 9805255 A MX9805255 A MX 9805255A MX 9805255 A MX9805255 A MX 9805255A MX 9805255 A MX9805255 A MX 9805255A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- vitronectin receptor
- vitronectin
- osteoporosis
- formulae
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US936695P | 1995-12-29 | 1995-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9805255A true MX9805255A (es) | 1998-11-29 |
Family
ID=21737205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9805255A MX9805255A (es) | 1995-12-29 | 1998-06-26 | Antagonistas de receptor de vitronectina. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0869787A4 (hu) |
| JP (1) | JP2000502354A (hu) |
| KR (1) | KR19990076878A (hu) |
| CN (1) | CN1209744A (hu) |
| AU (1) | AU1354097A (hu) |
| BR (1) | BR9612327A (hu) |
| CA (1) | CA2241633A1 (hu) |
| CZ (1) | CZ203698A3 (hu) |
| HU (1) | HUP9900754A3 (hu) |
| IL (1) | IL125033A0 (hu) |
| MX (1) | MX9805255A (hu) |
| NO (1) | NO983003L (hu) |
| PL (1) | PL327694A1 (hu) |
| TR (1) | TR199801253T2 (hu) |
| WO (1) | WO1997024119A1 (hu) |
| ZA (1) | ZA9610859B (hu) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030125317A1 (en) | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6218387B1 (en) * | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| DE19653645A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| WO1999006049A1 (en) * | 1997-08-04 | 1999-02-11 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| EP1047425A4 (en) * | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| US6420558B1 (en) | 1998-04-09 | 2002-07-16 | Meiji Seika Kaisha, Ltd. | Aminopiperidine derivates as integrin αvβ3 antagonists |
| DK1086086T3 (da) | 1998-06-12 | 2005-01-24 | Sod Conseils Rech Applic | Imidazolylderivater og anvendelse deraf som somatostatinreceptorligander |
| SE9803518D0 (sv) * | 1998-10-15 | 1998-10-15 | Astra Pharma Prod | Novel compounds |
| US6339083B1 (en) | 1998-12-14 | 2002-01-15 | Bayer Aktiengesellschaft | Multiheterocyclic pharmAceuticals |
| AU747503B2 (en) | 1999-02-03 | 2002-05-16 | Merck & Co., Inc. | Benzazepine derivatives as alpha-V integrin receptor antagonists |
| US6380210B1 (en) | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6281237B1 (en) | 1999-04-02 | 2001-08-28 | Neurogen Corporation | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives |
| US6358949B1 (en) | 1999-04-02 | 2002-03-19 | Neurogen Corporation | Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors |
| US6627624B1 (en) | 1999-04-02 | 2003-09-30 | Neurogen Corporation | Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
| BR0009539A (pt) * | 1999-04-02 | 2006-06-06 | Neurogen Corp | composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto |
| GB9908355D0 (en) * | 1999-04-12 | 1999-06-09 | Rhone Poulenc Rorer Ltd | Chemical compounds |
| AU5826100A (en) * | 1999-07-13 | 2001-01-30 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
| CA2378860A1 (en) | 1999-07-21 | 2001-02-01 | American Home Products Corporation | Bicyclic antagonists selective for the .alpha.v.beta.3 integrin |
| WO2001010844A1 (en) | 1999-08-05 | 2001-02-15 | Meiji Seika Kaisha, Ltd. | φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM |
| AU6523200A (en) * | 1999-08-06 | 2001-03-05 | Smithkline Beecham Corporation | Vitronectin receptor antagonists useful for the treatment of strokes |
| WO2001056995A1 (en) | 2000-01-18 | 2001-08-09 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
| US6545029B2 (en) | 2000-06-12 | 2003-04-08 | Bayer Aktiengesellschaft | Phenylserine derivatives as integrin antagonists |
| ATE360620T1 (de) | 2000-08-01 | 2007-05-15 | Sod Conseils Rech Applic | Imidazolderivate |
| US20040136949A1 (en) | 2001-04-24 | 2004-07-15 | Matthias Grell | Combination therapy using anti-angiogenic agents and tnf alpha |
| US7030150B2 (en) * | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
| EP2428226A1 (en) | 2001-10-22 | 2012-03-14 | The Scripps Research Institute | Antibody targeting compounds |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| BRPI0410746A (pt) * | 2003-05-19 | 2006-06-27 | Irm Llc | compostos e composições imunossupressoras |
| JP2007531773A (ja) | 2004-03-31 | 2007-11-08 | レキシコン・ジェネティクス・インコーポレーテッド | プロテインキナーゼ変調剤としての２−アミノメチルチアゾール−５−カルボキサミド |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| KR20070049655A (ko) | 2004-08-13 | 2007-05-11 | 제넨테크, 인크. | Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도 |
| EP2338518A1 (en) | 2006-01-18 | 2011-06-29 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
| MX2009007597A (es) | 2007-01-18 | 2009-07-22 | Merck Patent Gmbh | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. |
| WO2008141081A1 (en) | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2010093706A2 (en) | 2009-02-10 | 2010-08-19 | The Scripps Research Institute | Chemically programmed vaccination |
| BRPI1011206A2 (pt) | 2009-05-25 | 2016-03-15 | Merck Patent Gmbh | administração contínua de ligantes de integrina para tratar câncer |
| KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| PT3697785T (pt) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Compostos de imidazopiridina como inibidores de pad |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3627754A (en) * | 1970-05-13 | 1971-12-14 | Hoffmann La Roche | Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts |
| US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
-
1996
- 1996-12-20 PL PL96327694A patent/PL327694A1/xx unknown
- 1996-12-20 AU AU13540/97A patent/AU1354097A/en not_active Abandoned
- 1996-12-20 WO PCT/US1996/020748 patent/WO1997024119A1/en not_active Application Discontinuation
- 1996-12-20 HU HU9900754A patent/HUP9900754A3/hu unknown
- 1996-12-20 CA CA002241633A patent/CA2241633A1/en not_active Abandoned
- 1996-12-20 BR BR9612327A patent/BR9612327A/pt unknown
- 1996-12-20 CZ CZ982036A patent/CZ203698A3/cs unknown
- 1996-12-20 CN CN96180113A patent/CN1209744A/zh active Pending
- 1996-12-20 IL IL12503396A patent/IL125033A0/xx unknown
- 1996-12-20 EP EP96945087A patent/EP0869787A4/en not_active Withdrawn
- 1996-12-20 JP JP9524557A patent/JP2000502354A/ja active Pending
- 1996-12-20 TR TR1998/01253T patent/TR199801253T2/xx unknown
- 1996-12-20 KR KR1019980705005A patent/KR19990076878A/ko not_active Application Discontinuation
- 1996-12-23 ZA ZA9610859A patent/ZA9610859B/xx unknown
-
1998
- 1998-06-26 MX MX9805255A patent/MX9805255A/es unknown
- 1998-06-26 NO NO983003A patent/NO983003L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997024119A1 (en) | 1997-07-10 |
| HUP9900754A2 (hu) | 1999-07-28 |
| NO983003L (no) | 1998-08-26 |
| HUP9900754A3 (en) | 1999-11-29 |
| NO983003D0 (no) | 1998-06-26 |
| CA2241633A1 (en) | 1997-07-10 |
| AU1354097A (en) | 1997-07-28 |
| BR9612327A (pt) | 1999-07-13 |
| EP0869787A4 (en) | 1999-03-24 |
| TR199801253T2 (xx) | 1998-12-21 |
| PL327694A1 (en) | 1998-12-21 |
| ZA9610859B (en) | 1997-10-24 |
| IL125033A0 (en) | 1999-01-26 |
| EP0869787A1 (en) | 1998-10-14 |
| CZ203698A3 (cs) | 1999-05-12 |
| JP2000502354A (ja) | 2000-02-29 |
| CN1209744A (zh) | 1999-03-03 |
| KR19990076878A (ko) | 1999-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9805255A (es) | Antagonistas de receptor de vitronectina. | |
| MX9805253A (es) | Antagonistas del receptor de vitronectina. | |
| ZA9610854B (en) | Vitronectin receptor antagonists. | |
| AP1463A (en) | Vitronectin receptor antagonists. | |
| MY108579A (en) | Endothelin receptor antagonists | |
| BG102690A (en) | Il-8 receptor antagonists | |
| ZA967084B (en) | Cement formulation. | |
| ZA948541B (en) | Endothelin receptor antagonists | |
| YU15299A (sh) | Farmaceutski sastavi | |
| PT1036058E (pt) | Deribvados de adamantano | |
| PT1036059E (pt) | Derivados de adamantano | |
| BG103548A (en) | Vitronectine receptor antagonists | |
| HUP9600256A3 (en) | Substituted diphenyl-sulfonamide endothelin antagonists, pharmaceutical compositions containing the same and their medical uses | |
| AP9701029A0 (en) | Indole derivatives useful in the treatment of osteoporosis | |
| HK1012252A1 (en) | Endothelin receptor antagonists | |
| BG104038A (en) | Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing | |
| IL115589A0 (en) | Use of cck-b antagonists in pharmaceutical compositions | |
| HUP9902817A3 (en) | Endothelin receptor antagonists | |
| HU9602054D0 (en) | Endothelin receptor antagonists | |
| EP0854721A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
| WO2000007544A3 (en) | Vitronectin receptor antagonists | |
| EP0828493A4 (en) | 4.4-DISUBSTITUTED CYCLOHEXANE-1-OL MONOMERS AND RELATED COMPOUNDS | |
| EP0711157A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
| EP0868180A4 (en) | ENDOTHELINM RECEPTOR ANTOGONISTS | |
| GB9525291D0 (en) | The anti-swing chair |